Sano blog | precision medicine

The Genetics Podcast featuring Timothy Yu

precision medicine rare disease podcast recap

Podcast recap: Tim Yu on the rise of N-of-1 genetic medicines

Most genetic medicine is built for populations large enough to support a clinical trial. N-of-1 medicine is built for the opposite case: a single patient whose ...

precision medicine patient recruitment genetic testing patient engagement

FDA gene therapy guidance exposes patient recruitment gap

On June 2, 2026, the FDA released draft guidance that could reshape how gene therapies reach patients. The document, "Leveraging Prior Knowledge in the Developm...

precision medicine Alzheimer's disease podcast recap

What four episodes of The Genetics Podcast reveal about the future of Alzheimer’s precision medicine

Alzheimer’s research is entering a new phase. For decades, the field has been shaped by the biology of amyloid plaques and tau tangles. Those remain central to ...

Patient engagement through the precision medicine lifecycle

precision medicine patient engagement

The long game: Precision trials shouldn’t start from zero every time

Precision medicine sponsors invest heavily to identify, educate, screen, consent, genotype, and support rare patients. In many programs, once a trial ends, that...

precision medicine data privacy patient engagement

Trust is the foundation of precision medicine

UK Biobank and similar resources have made an extraordinary contribution to biomedical research, enabling important advances across genomics, population health,...

precision medicine patient recruitment genetic testing

How Sano enables precision patient finding at scale

Recruitment in precision medicine and rare disease trials remains constrained by fragmented data, low prevalence populations, and heavy reliance on site-based p...

precision medicine rare disease

The rare disease blueprint: What precision medicine can learn from the hardest trials

Rare disease exposes the limits of current clinical development models. Small, fragmented populations make patient identification difficult. Heterogeneous biolo...

Genomics-driven drug development in pharma

precision medicine thought leadership rare disease

The forces shaping regulatory expectations in genomics-driven pharma

Regulatory expectations in genomics-driven drug development are evolving alongside scientific practice, clinical implementation, and policy. While formal guidan...

precision medicine protocol design

Lessons from recent FDA actions in precision medicine

Over the past few years, several cell and gene therapies (CGTs) in precision medicine have received FDA Complete Response Letters (CRLs). As the agency increase...

The Genetics Podcast featuring Rachel Salzman